Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last C$3.18 CAD
Change Today -0.12 / -3.64%
Volume 33.9K
I On Other Exchanges
Symbol
Exchange
Toronto
NASDAQ CM
Frankfurt
As of 3:59 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

intellipharmaceutics interna (I) Snapshot

Open
C$3.33
Previous Close
C$3.30
Day High
C$3.33
Day Low
C$3.01
52 Week High
04/29/14 - C$5.15
52 Week Low
08/27/14 - C$2.14
Market Cap
74.9M
Average Volume 10 Days
13.8K
EPS TTM
C$-0.30
Shares Outstanding
23.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for INTELLIPHARMACEUTICS INTERNA (I)

Related News

No related news articles were found.

intellipharmaceutics interna (I) Related Businessweek News

No Related Businessweek News Found

intellipharmaceutics interna (I) Details

Intellipharmaceutics International Inc., a pharmaceutical company, engages in the research, development, and manufacture of novel and generic controlled and targeted release oral solid dosage drugs in Canada. The company develops various drug delivery systems and a pipeline of products based on its patented Hypermatrix technology in various stages of development in therapeutic areas, such as neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. Its products under abbreviated new drug application stage include Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorders; Effexor XR, a venlafaxine hydrochloride extended-release capsule for depression; Protonix, a tablet for gastroesophageal reflux diseases; Glucophage XR, a tablet for managing type 2 diabetes; Seroquel XR, a tablet for the treatment of schizophrenia, as well as bipolar and depressive disorders; Lamictal XR, a tablet for anti-convulsant for epilepsy; Keppra XR, a tablet for the treatment of partial onset seizures for epilepsy; and Pristiq, a tablet for depression. The company is also developing Oleptro, a trazodone hydrochloride extended release tablet for treating depression; Coreg CR, a capsule, which is in late-stage development for heart failure and hypertension; OxyContin, a controlled release capsule that is in phase I clinical trial for pain; and Lyrica, a capsule, which is in phase I clinical trial for neuropathic pain. Its non-generic products under development include Rexista, an oral formulation for pain relief; and Regabati XR, a pregabalin extended release capsule that has completed an initial phase I clinical trial for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury, and fibromyalgia. The company has a license and commercialization agreement with Par Pharmaceutical, Inc. Intellipharmaceutics International Inc. is headquartered in Toronto, Canada.

46 Employees
Last Reported Date: 02/27/15

intellipharmaceutics interna (I) Top Compensated Officers

Co-Founder, Chairman, Chief Executive Officer...
Total Annual Compensation: $582.0K
President, Chief Operating Officer and Direct...
Total Annual Compensation: $582.0K
Chief Financial Officer
Total Annual Compensation: $5.2K
Vice President of Legal Affairs & Licensing, ...
Total Annual Compensation: $132.2K
Compensation as of Fiscal Year 2014.

intellipharmaceutics interna (I) Key Developments

Intellipharmaceutics International Inc. Announces Unaudited Consolidated Earnings Results for the First Quarter Ended February 28, 2015

Intellipharmaceutics International Inc. announced unaudited consolidated earnings results for the first quarter ended February 28, 2015. For the quarter, the company revenue was $1,139,685 compared with $4,681,058 a year ago. Loss from operations was $847,266 compared with income from operations was $2,245,287 a year ago. Net loss and comprehensive loss was $914,660 or 0.04 basic and diluted per share compared with net income and comprehensive income of $2,201,435 or 0.09 basic and diluted per share a year ago. Cash flow used in operating activities was $127,547 compared with cash flow provided from operating activities was $217,123 a year ago. Purchase of property and equipment was $31,493 compared with $65,650 a year ago.

Intellipharmaceutics International Inc. Announces Positive Phase I Pain Trials

Intellipharmaceutics International Inc. announced results of three definitive open label, blinded, randomized, crossover, Phase I pharmacokinetic clinical trials in which Rexista Oxycodone XR, intended for the management of moderate to severe pain, was compared to Oxycontin under single dose fasting, single dose steady-state fasting and single dose fed conditions in healthy volunteers. Intellipharmaceutics has received topline data results from all three studies. The first study, a single dose steady-state fasting study, showed that Rexista Oxycodone XR met the bioequivalence criteria (90% confidence interval of 80% to 125%) for all matrices, i.e., on the measure of maximum plasma concentration or Cmax, the ratio of Rexista Oxycodone XR to Oxycontin was 94.95% (90% confidence interval of 81.29% to 110.89%) and on the measure of area under the curve steady state (AUCss) the ratio of Rexista Oxycodone XR to Oxycontin was 100.54% (90% confidence interval of 89.97% to 112.34%). The second study, a single dose fasting study, showed that Rexista Oxycodone XR met the bioequivalence criteria (90% confidence interval of 80% to 125%) for all matrices, i.e., on the measure of maximum plasma concentration or Cmax, the ratio of Rexista Oxycodone XR to Oxycontin was 92.69% (90% confidence interval of 80.26% to 107.04%), on the measure of area under the curve time (AUCt) the ratio of Rexista Oxycodone XR to Oxycontin was 100.53% (90% confidence interval of 95.13% to 106.53%) while on the measure of area under the curve infinity (AUCinf) the ratio of Rexista Oxycodone XR to Oxycontin was 114.87% (90% confidence interval of 108.21% to 121.93%). The third study, a single dose fed study, showed that Rexista Oxycodone XR met the bioequivalence criteria (90% confidence interval of 80% to 125%) for all matrices, i.e., on the measure of maximum plasma concentration or Cmax, the ratio of Rexista Oxycodone XR to Oxycontin was 91.66% (90% confidence interval of 80.21% to 104.75%), on the measure of area under the curve time (AUCt) the ratio of Rexista Oxycodone XR to Oxycontin was 103.21% (90% confidence interval of 94.15% to 113.15%) while on the measure of area under the curve infinity (AUCinf) the ratio of Rexista Oxycodone XR to Oxycontin was 107.39% (90% confidence interval of 98.62% to 107.39%). Rexista Oxycodone XR is a non-generic extended release formulation intended for the management of moderate to severe pain when an around-the-clock analgesic is required.

IntelliPharmaCeutics International Inc. Provides Update on Product Development Programs

Intellipharmaceutics International Inc. announced that it has provided an update on the progress of the product development programs for both its Rexista Oxycodone Abuse Deterrent oxycodone hydrochloride extended release tablets and for its Regabatin XR once daily, non-generic extended release version of pregabalin. Rexista Oxycodone XR is a non-generic extended release formulation intended for the management of moderate to severe pain when an around-the-clock analgesic is required. The formulation is intended to present a significant barrier to tampering when subjected to various forms of anticipated physical and chemical manipulation commonly used by abusers. It is also designed to prevent dose dumping when inadvertently co-administered with alcohol. In addition, when crushed or pulverized and hydrated, the proposed extended release formulation is designed to coagulate instantaneously and entrap the drug in a viscous hydrogel, which is intended to prevent syringing, injecting and snorting. The company recently submitted an Investigational New Drug Application to the United States Food and Drug Administration for Rexista Oxycodone XR in anticipation of the commencement of Phase III clinical trials. Planning has begun for the Phase III trials that will examine the efficacy and safety of Rexista Oxycodone XR in individuals with chronic low back pain. The company has recently conducted and analyzed the results of three definitive open label, blinded, randomized, crossover, Phase I pharmacokinetic clinical trials in which Rexista Oxycodone XR was compared to Oxycontin under single dose fasting, single dose steady-state fasting and single dose fed conditions in healthy volunteers. The company has received topline data results from all three studies. The first study, a single dose steady-state fasting study, showed that RexistaTM Oxycodone XR met the bioequivalence criteria (90% confidence interval of 80% to 125%) for all matrices, i.e., on the measure of maximum plasma concentration or Cmax, the ratio of RexistaT Oxycodone XR to Oxycontin was 94.95% and on the measure of area under the curve steady state the ratio of Rexista Oxycodone XR to Oxycontin was 100.54%. The second study, a single dose fasting study, showed that Rexista Oxycodone XR met the bioequivalence criteria for all matrices, i.e., on the measure of maximum plasma concentration or Cmax, the ratio of Rexista Oxycodone XR to Oxycontin® was 92.69%, on the measure of area under the curve time (AUCt) the ratio of Rexista Oxycodone XR to Oxycontin was 100.53% while on the measure of area under the curve infinity (AUCinf) the ratio of Rexista Oxycodone XR to Oxycontin was 114.87%. The third study, a single dose fed study, showed that Rexista Oxycodone XR met the bioequivalence criteria for all matrices, i.e., on the measure of maximum plasma concentration or Cmax, the ratio of Rexista Oxycodone XR to Oxycontin was 91.66%, on the measure of area under the curve time (AUCt) the ratio of Rexista Oxycodone XR to Oxycontin was 103.21% while on the measure of area under the curve infinity (AUCinf) the ratio of RexistaOxycodone XR to Oxycontin was 107.39%. Regabatin XR: The company also reported that the FDA has accepted a Pre-Investigational New Drug (Pre-IND) meeting request for its once-a-day Regabatin XR non-generic controlled release version of pregabalin under the new drug application ("NDA") 505(b) (2) regulatory pathway, with a view to possible commercialization in the United States at some time following the December 30, 2018 expiry of the patent covering the pregabalin molecule. Regabatin XR is based on the company's controlled release drug delivery technology platform which utilizes the symptomatology and chronobiology of fibromylagia in a formulation intended to provide a higher exposure of pregabalin during the first twelve hours of dosing. Pregabalin is indicated for the management of neuropathic pain associated with diabetic peripheral neuropathy, postherpetic neuralgia, spinal cord injury and fibromyalgia. A once-a-day controlled release version of pregabalin should reduce the number of doses patients currently take, potentially improving patient compliance, and thereby potentially improving clinical outcomes. This Pre-IND request with the FDA is focused on the Company's proposed Phase III clinical program. There can be no assurance that additional clinical trials will meet expectations, that the company will have sufficient capital to conduct such trials, that the company will be successful in submitting any NDA with the FDA, that the FDA will approve these product candidates for sale in the U.S. market, or that they will ever be successfully commercialized.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
I:CN C$3.18 CAD -0.12

I Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,750 GBp -78.50
Durect Corp $1.92 USD -0.01
Lupin Ltd 1,770 INR 0.00
Torrent Pharmaceuticals Ltd 1,281 INR 0.00
View Industry Companies
 

Industry Analysis

I

Industry Average

Valuation I Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 11.7x
Price/Book 14.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 10.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INTELLIPHARMACEUTICS INTERNA, please visit www.intellipharmaceutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.